These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 9025097)
1. Mutagenicity of the potent rat hepatocarcinogen 6BT to the liver of transgenic (lacI) rats: consideration of a reduced mutation assay protocol. Lefevre PA; Tinwell H; Ashby J Mutagenesis; 1997 Jan; 12(1):45-7. PubMed ID: 9025097 [TBL] [Abstract][Full Text] [Related]
2. Hepatic gene mutations induced in Big Blue rats by both the potent rat liver azo-carcinogen 6BT and its reported noncarcinogenic analogue 5BT. Fletcher K; Soames AR; Tinwell H; Lefevre PA; Ashby J Environ Mol Mutagen; 1999; 34(2-3):148-53. PubMed ID: 10529739 [TBL] [Abstract][Full Text] [Related]
3. Use of an in vivo/in vitro rat liver DNA repair assay to predict the relative rodent hepatocarcinogenic potency of 3 new azo mutagens. Beije B; Ashby J Carcinogenesis; 1985 Apr; 6(4):611-5. PubMed ID: 3921275 [TBL] [Abstract][Full Text] [Related]
4. 6-p-Dimethylaminophenylazobenzothiazole: a potent hepatocarcinogen in the rat. Elliott BM; Robinson M; Ashby J Cancer Lett; 1983 Nov; 21(1):69-76. PubMed ID: 6416666 [TBL] [Abstract][Full Text] [Related]
5. Gene- and tissue-specificity of mutation in Big Blue rats treated with the hepatocarcinogen N-hydroxy-2-acetylaminofluorene. Chen T; Mittelstaedt RA; Shelton SD; Dass SB; Manjanatha MG; Casciano DA; Heflich RH Environ Mol Mutagen; 2001; 37(3):203-14. PubMed ID: 11317338 [TBL] [Abstract][Full Text] [Related]
6. Tamoxifen induces G:C-->T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5'-CpG-3' dinucleotide sequences as found in the lacI transgene. Davies R; Gant TW; Smith LL; Styles JA Carcinogenesis; 1999 Jul; 20(7):1351-6. PubMed ID: 10383911 [TBL] [Abstract][Full Text] [Related]
7. Comparison of hprt and lacI mutant frequency with DNA adduct formation in N-hydroxy-2-acetylaminofluorene-treated Big Blue rats. Chen T; Mittelstaedt RA; Aidoo A; Hamilton LP; Beland FA; Casciano DA; Heflich RH Environ Mol Mutagen; 2001; 37(3):195-202. PubMed ID: 11317337 [TBL] [Abstract][Full Text] [Related]
8. Differential in vivo mutagenicity of the carcinogen/non-carcinogen pair 2,4- and 2,6-diaminotoluene. Hayward JJ; Shane BS; Tindall KR; Cunningham ML Carcinogenesis; 1995 Oct; 16(10):2429-33. PubMed ID: 7586147 [TBL] [Abstract][Full Text] [Related]
9. Mutational spectra of tamoxifen-induced mutations in the livers of lacI transgenic rats. Davies R; Oreffo VI; Bayliss S; Dinh PA; Lilley KS; White IN; Smith LL; Styles JA Environ Mol Mutagen; 1996; 28(4):430-3. PubMed ID: 8991074 [TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of the liver, colon and kidney of Big Blue rats treated with 2-amino-3-methylimidazo[4,5-f]quinoline. Bol SA; Horlbeck J; Markovic J; de Boer JG; Turesky RJ; Constable A Carcinogenesis; 2000 Jan; 21(1):1-6. PubMed ID: 10607726 [TBL] [Abstract][Full Text] [Related]
11. Species-specific differences in hepatic mutant frequency and mutational spectrum among lambda/lacI transgenic rats and mice following exposure to aflatoxin B1. Dycaico MJ; Stuart GR; Tobal GM; de Boer JG; Glickman BW; Provost GS Carcinogenesis; 1996 Nov; 17(11):2347-56. PubMed ID: 8968048 [TBL] [Abstract][Full Text] [Related]
12. Mutagenic response of the endogenous hprt gene and lacI transgene in benzo[a]pyrene-treated Big Blue B6C3F1 mice. Skopek TR; Kort KL; Marino DR; Mittal LV; Umbenhauer DR; Laws GM; Adams SP Environ Mol Mutagen; 1996; 28(4):376-84. PubMed ID: 8991066 [TBL] [Abstract][Full Text] [Related]
13. Positive and negative control observations for the in vivo/in vitro rat liver assay for unscheduled DNA synthesis (UDS). Ashby J; Trueman RW; Mohammed R; Barber G Mutagenesis; 1987 Nov; 2(6):489-90. PubMed ID: 3127659 [TBL] [Abstract][Full Text] [Related]
14. The disposition and in vivo covalent binding to liver DNA of the monoazodyes 6-(p-dimethylaminophenylazo)benzothiazole (6BT) and 5-(p-dimethylaminophenylazo)indazole (5I) after administration to the rat. Dashwood RH; Combes RD; Ashby J Carcinogenesis; 1986 Jun; 7(6):1029-33. PubMed ID: 3085965 [TBL] [Abstract][Full Text] [Related]
15. Distinction of mutagenic carcinogens from a mutagenic noncarcinogen in the big blue transgenic mouse. Cunningham ML; Hayward JJ; Shane BS; Tindall KR Environ Health Perspect; 1996 May; 104 Suppl 3(Suppl 3):683-6. PubMed ID: 8781405 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the in vivo genotoxic potential of three carcinogenic aromatic amines using the Big Blue transgenic mouse mutation assay. Suter W; Ahiabor R; Blanco B; Locher F; Mantovani F; Robinson M; Sreenan G; Staedtler F; Swingler T; Vignutelli A; Perentes E Environ Mol Mutagen; 1996; 28(4):354-62. PubMed ID: 8991064 [TBL] [Abstract][Full Text] [Related]
17. 1,3-butadiene: cancer, mutations, and adducts. Part II: Roles of two metabolites of 1,3-butadiene in mediating its in vivo genotoxicity. Recio L; Saranko CJ; Steen AM Res Rep Health Eff Inst; 2000 Mar; (92):49-87; discussion 141-9. PubMed ID: 10925839 [TBL] [Abstract][Full Text] [Related]
18. Comparison of in vivo mutagenesis in the endogenous Hprt gene and the lacI transgene of Big Blue(R) rats treated with 7, 12-dimethylbenz[a]anthracene. Manjanatha MG; Shelton SD; Aidoo A; Lyn-Cook LE; Casciano DA Mutat Res; 1998 Jun; 401(1-2):165-78. PubMed ID: 9639698 [TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of lacI mutations in Rat2 cells exposed to 7,12-dimethylbenz[a]anthracene: evidence for DNA sequence and DNA strand biases for mutation. Manjanatha MG; Chen JB; Shaddock JG; Harris AJ; Shelton SD; Casciano DA Mutat Res; 1996 Nov; 372(1):53-64. PubMed ID: 9003531 [TBL] [Abstract][Full Text] [Related]
20. Comparison of mutant frequencies at the transgenic lambda LacI and cII/cI loci in control and ENU-treated Big Blue mice. Zimmer DM; Harbach PR; Mattes WB; Aaron CS Environ Mol Mutagen; 1999; 33(3):249-56. PubMed ID: 10334627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]